Pharmacology and Clinical Use of the New ACE‐Inhibitor Moexipril

[1]  R. W. Fleming,et al.  Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types. , 1986, Journal of medicinal chemistry.

[2]  P. Vanhoutte,et al.  Bradykinin stimulates the production of cyclic GMP via activation of B2 kinin receptors in cultured porcine aortic endothelial cells. , 1990, The Journal of pharmacology and experimental therapeutics.

[3]  M. Stimpel,et al.  Comparison of moexipril, a new ACE inhibitor, to verapamil-SR as add-on therapy to low dose hydrochlorothiazide in hypertensive patients. , 1995, American journal of hypertension.

[4]  K. Kripalani,et al.  Pharmacokinetics of fosinopril in patients with various degrees of renal function , 1991, Clinical pharmacology and therapeutics.

[5]  R. Heel,et al.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. , 1986, Drugs.

[6]  J. Reid,et al.  Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs. , 1991, British journal of clinical pharmacology.

[7]  Antihypertensive Effects of Moexipril, a New ACE Inhibitor, as Add‐On Therapy to Nifedipine in Patients with Essential Hypertension , 1995, Journal of cardiovascular pharmacology.

[8]  W. White,et al.  Long-term efficacy and safety of moexipril in the treatment of hypertension. , 1994, Journal of human hypertension.

[9]  S. Singhvi,et al.  Disposition of fosinopril sodium in healthy subjects. , 1988, British journal of clinical pharmacology.

[10]  W. White,et al.  Tricenter Assessment of the Efficacy of the ACE Inhibitor, Moexipril, by Ambulatory Blood Pressure Monitoring , 1995, Journal of clinical pharmacology.

[11]  K. Dickstein,et al.  Comparison of the efficacy of three dose levels of moexipril versus placebo as add-on therapy to hydrochlorothiazide in patients with moderate hypertension. , 1994, Journal of cardiovascular pharmacology.

[12]  D. Campbell,et al.  Circulating and tissue angiotensin systems. , 1987, The Journal of clinical investigation.

[13]  P. Benfield,et al.  Ramipril , 2012, Drugs.

[14]  M. Peach,et al.  Angiotensin II Induces Hypertrophy, not Hyperplasia, of Cultured Rat Aortic Smooth Muscle Cells , 1988, Circulation research.

[15]  P. A. Todd,et al.  Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. , 1988, Drugs.

[16]  D R Abernethy,et al.  Moexipril in the Treatment of Mild to Moderate Essential Hypertension: Comparison with Sustained‐Release Verapamil , 1995, Journal of clinical pharmacology.

[17]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[18]  J. Swales.  The renin-angiotensin system as a target for therapeutic intervention. , 1994, Journal of cardiovascular pharmacology.

[19]  L. Juillerat-Jeanneret,et al.  Involvement of the kallikrein-kinin system in the antihypertensive effect of the angiotensin converting enzyme inhibitors. , 1989, British journal of clinical pharmacology.

[20]  Y. Nakamura,et al.  Altered noradrenergic projection to hypothalamus via baroreflex in spontaneously hypertensive rats. , 1991, American Journal of Hypertension.

[21]  K. Goa,et al.  Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure. , 1991, Drugs.

[22]  K. Lasseter,et al.  The disposition of [14C]-labelled benazepril HCl in normal adult volunteers after single and repeated oral dose. , 1991, Xenobiotica; the fate of foreign compounds in biological systems.

[23]  K. Kohara,et al.  Left ventricular mass index negatively correlates with heart rate variability in essential hypertension. , 1995, American journal of hypertension.

[24]  R. Parish,et al.  Adverse Effects of Angiotensin Converting Enzyme (ACE) Inhibitors , 1992, Drug safety.

[25]  A. Fitton,et al.  Perindopril. A review of its pharmacological properties and therapeutic use in cardiovascular disorders. , 1991, Drugs.

[26]  J. Massarella,et al.  The influence of food on the pharmacokinetics and ACE inhibition of cilazapril. , 1989, British journal of clinical pharmacology.

[27]  B. Massie,et al.  A Comparison of the Efficacy and Safety of a β-Blocker, a Calcium Channel Blocker, and a Converting Enzyme Inhibitor in Hypertensive Blacks , 1990 .